125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts

Clinical Cancer Research

Volumn 5, Issue 6, 1999, Pages 1539-1549

  Kuan, Chien Tsun ^a   Reist, Craig J ^a   Foulon, Catherine F ^a   Lorimer, Ian A J ^b   Archer, Gary ^a   Pegram, Charles N ^a   Pastan, Ira ^c   Zalutsky, Michael R ^a   Bigner, Darell D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b OTTAWA REGIONAL CANCER CENTRE   (Canada)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; IODINE 125; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY H10; MONOCLONAL ANTIBODY L8A4; UNCLASSIFIED DRUG; RADIOACTIVE IODINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG TUMOR LEVEL; DRUG UPTAKE; FEMALE; GLIOMA; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RADIOISOTOPE DISTRIBUTION; RADIOISOTOPE THERAPY; THERMOSTABILITY; AMINO ACID SEQUENCE; ANIMAL; ANTIBODY SPECIFICITY; BINDING COMPETITION; CANCER TRANSPLANTATION; CHEMISTRY; GENETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN FOLDING; TISSUE DISTRIBUTION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODY SPECIFICITY; BINDING, COMPETITIVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; GLIOMA; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; IODINE RADIOISOTOPES; MICE; MOLECULAR SEQUENCE DATA; NEOPLASM TRANSPLANTATION; PROTEIN FOLDING; RECEPTOR, EPIDERMAL GROWTH FACTOR; TISSUE DISTRIBUTION;

EID: 0032586898     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Ehrlich, P. Collected Studies in Immunity. New York: J. Wiley & Sons, 1905.
2. Huston, J. S., George, A. J., Adams, G. P., Stafford, W. F., Jamar, F., Tai, M. S., McCartney, J. E., Oppermann, H., Heelan, B. T., Peters, A. M., Houston, L. L., Bookman, M. A., Wolf, E. J., and Weiner, L. M. Single-chain Fv radioimmunotargeting. Q. J. Nucl. Med., 40: 320-333, 1996.
3. Reisfeld, R. A., and Gillies, S. D. Recombinant antibody fusion proteins for cancer immunotherapy. Curr. Top. Microbiol. Immunol., 213: 27-53, 1996.
4. Winter, G., Griffiths, A. D., Hawkins, R. E., and Hoogenboom, H. R. Making antibodies by phage display technology. Annu. Rev. Immunol., 12: 433-455, 1994.
5. 131I]anti-B1 (anti-CD20) antibody. N. Engl. J. Med., 329: 459-465, 1993.
6. Kaminski, M. S., Zasadny, K. R., Francis, I. R., Fenner, M. C., Ross, C. W., Milik, A. W., Estes, J., Tuck, M., Regan, D., Fisher, S., Glenn, S. D., and Wahl, R. L. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J. Clin. Oncol., 14: 1974-1981, 1996.
7. Press, O. W., Eary, J. F., Appelbaum, F. R., Martin, P. J., Badger, C. C., Nelp, W. B., Glenn, S., Butchko, G., Fisher, D., Porter, B., Matthews, D. C., Fisher, L. D., and Bernstein, I. D. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl. J. Med., 329: 1219-1224, 1993.
8. Bigner, D. D., Brown, M. T., Friedman, A. H., Coleman, R. E., Akabani, G., Friedman, H. S., Thorstad, W. L., McLendon, R. E., Bigner, S. H., Zhao, X. G., Pegram, C. N., Wikstrand, C. J., Herndon, J. N., Vick, N. A., Paleologos, N., Cokgor, I., Provenzale, J. M., and Zalutsky, M. R. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: Phase I trial results. J. Clin. Oncol., 16: 2202-2212, 1998.
9. 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: Phase I trial results. Clin. Cancer Res., 2: 963-972, 1996.
10. Pastan, I. H., Archer, G. E., McLendon, R. E., Friedman, H. S., Fuchs, H. E., Wang, Q-C., Pai, L. H., Herndon, J., and Bigner, D. D. Intrathecal administration of a single-chain immunotoxin, LMB-7 [B3(Fv)-PE38], produces cures of carcinomatous meningitis in a rat model. Proc. Natl. Acad. Sci. USA, 92: 2765-2769, 1995.
11. Morrison, P. F., Laske, D. W., Bobo, H., Oldfield, E. H., and Dedrick, R. L. High-flow microinfusion: tissue penetration and pharmacodynamics. Am. J. Physiol., 266: R292-R305, 1994.
12. Laske, D. W., Youle, R. J., and Oldfield, E. H. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat. Med., 3: 1362-1368, 1997.
13. Raag, R., and Whitlow, M. Single-chain Fvs. FASEB J., 9: 73-80, 1995.
14. Yokota, T., Milenic, D. E., Withlow, M., and Schlom, J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res., 52: 3402-3408, 1992.
15. Huston, J. S., Levinson, D., Mudgett-Hunter, M., Tai, M. S., Novotny, J., Margolies, M. N., Ridge, R. J., Bruccoleri, E. H., Crea, R., and Oppermann, H. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxigenin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. USA, 85: 5879-5883, 1988.
16. Brinkmann, U., Pai, L. H., FitzGerald, D. J., Willingham, M., and Pastan, I. B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc. Natl. Acad. Sci. USA, 88: 8616-8620, 1991.
17. Chester, K. A., Begent, R. H., Robson, L., Keep, P., Pedley, R. B., Boden, J. A., Boxer, G., Green, A., Winter, G., Cochet, O., and Hawkins, R. E. Phage libraries for generation of clinically useful antibodies. Lancet, 343: 455-456, 1994.
18. Skerra, A. Bacterial expression of immunoglobulin fragments. Curr. Opin. Immunol., 5: 256-262, 1993.
19. Takkinen, K., Laukkanen, M. L., Sizmann, D., Alfthan, K., Immonen, T., Vanne, L., Kaartinen, M., Knowles, J. K., and Teeri, T. T. An active single-chain antibody containing a cellulase linker domain is secreted by Escherichia coli. Prot. Eng., 4: 837-841, 1991.
20. Jain, R., and Baxter, L. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res., 48: 7022-7033, 1988.
21. Milenic, D. E., Yokota, T., Filpula, D. R., Finkelman, M. A. J., Dodd, S. W., Wood, J. F., Withlow, M., Snoy, P., and Schlom, J. Construction, binding properties, metabolism, and tumor targeting of a single chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res., 51: 6363-6371, 1991.
22. Bigner, S. H., Humphrey, P. A., Wong, A. J., Vogelstein, B., Mark, J., Friedman, H. S., and Bigner, D. D. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res., 50: 8017-8022, 1990.
23. Yamazaki, H., Ohba, Y., Tamaoki, N., and Shibuya, M. A deletion mutation within the ligand binding domain is responsible for activation of epidermal growth factor receptor gene in human brain tumors. Jpn. J. Cancer Res., 81: 773-779, 1990.
24. Garcia de Palazzo, I. E., Adams, G., P., Sundareshan, P., Wong, A. J., Testa, J. R., Bigner, D. D., and Weiner, L. M. Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res., 53: 3217-3220, 1993.
25. Moscatello, D. K., Holgado-Madruga, M., Godwin, A. K., Ramirez, G., Gunn, G., Zoltick, P. W., Biegel, J. A., Hayes, R. L., and Wong, A. J. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res., 55: 5536-5539, 1995.
26. Wikstrand, C. J., Hale, L. P., Batra, S. K., Hill, M. L., Humphrey, P. A., Kurpad, S. N., McLendon, R. E., Moscatello, D., Pegram, C. N., Reist, C. J., Traweek, S. T., Wong, A. J., Zalutsky, M. R., and Bigner, D. D. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res., 55: 3140-3148, 1995.
27. Humphrey, P. A., Wong, A. J., Vogelstein, B., Zalutsky, M. R., Fuller, G. N., Archer, G. E., Friedman, H. S., Kwatra, M. M., Bigner, S. H., and Bigner, D. D. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc. Natl. Acad. Sci. USA, 87: 4207-4211, 1990.
28. Batra, S. K., Castelino-Prabhu, S., Wikstrand, C. J., Zhu, X., Humphrey, P. A., Friedman, H. S., and Bigner, D. D. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ., 6: 1251-1259, 1995.
29. Nishikawa, R., Ji, X-D., Harmon, R. C., Lazar, C. S., Gill, G. N., Cavanee, W. K., and Huang, H-J. S. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc. Natl. Acad. Sci. USA, 91: 7727-7731, 1994.
30. Reist, C. J., Garg, P. K., Alston, K. L., Bigner, D. D., and Zalutsky, M. R. Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridinecarboxylate. Cancer Res., 56: 4970-4977, 1996.
31. Reist, C. J., Archer, G. E., Wikstrand, C. J., Bigner, D. D., and Zalutsky, M. R. Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate. Cancer Res., 57: 1510-1515, 1997.
32. Lorimer, I. A., Keppler-Hafkemeyer, A., Beers, R. A., Pegram, C. N., Bigner, D. D., and Pastan, I. Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display. Proc. Natl. Acad. Sci. USA, 93: 14815-14820, 1996.
33. Larsen, R. H., and Bruland, O. S. Intratumour injection of immunoglobulins labelled with the α-particle emitter 211At: analyses of tumour retention, microdistribution and growth delay. Br. J. Cancer, 77: 1115-1122, 1998.
34. Otsuji, E., Yamaguchi, T., Tsuruta, H., Yata, Y., Nishi, H., Okamoto, K., Taniguchi, K., Kato, M., Kotani, T., Kitamura, K., and Takahashi, T. The effect of intravenous and intra-tumoural chemotherapy using a monoclonal antibody-drug conjugate in a xenograft model of pancreatic cancer. Eur. J. Surg. Oncol., 21: 61-65, 1995.
35. Borchardt, P. E., Quadri, S. M., Freedman, R. S., and Vriesendorp, H. M. Intralesional radiolabeled human monoclonal IgM in human tumor xenografts. Radiother. Oncol., 44: 283-293, 1997.
36. Bird, R. E., Hardman, K. D., Jacobson, J. W., Johnson, S., Kaufman, B. M., Lee, S-M., Lee, T., Pope, S. H., Riordan, G. S., and Withlow, M. Single-chain antigen binding proteins. Science (Washington DC), 242; 423-426, 1988.
37. Lindmo, T., Boven, E., Cuttitta, F., Fedorko, J., and Bunn, P., Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J. Immunol. Methods, 72: 77-89, 1984.
38. Chu, C. T., Everiss, K. D., Wikstrand, C. J., Batra, S. K., Kung, H. J., and Bigner, D. D. Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). Biochem. J., 324: 855-861, 1997.
39. Begent, R. H., Verhaar, M. J., Chester, K. A., Casey, J. L., Green, A. J., Napier, M. P., Hope-Stone, L. D., Cushen, N., Keep, P. A., Johnson, C. J., Hawkins, R. E., Hilson, A. J., and Robson, L. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat. Med., 2: 979-984, 1996.
40. Wels, W., Harwerth, I. M., Zwickl, M., Hardman, N., Groner, B., and Hynes, N. E. Construction, bacterial expression and characterization of a bifunctional single-chain antibody-phosphatase fusion protein targeted to the human erbB-2 receptor. Biotechnology, 10: 1128-1132, 1992.
41. Holliger, P., Prospero, T., and Winter, G. "Diabodies": small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. USA, 90: 6444-6448, 1993.
42. Adams, G. P., McCartney, J. E., Tai, M. S., Oppermann, H., Huston, J. S., Stafford, W. D., Bookman, M. A., Fand, I., Houston, L. L., and Weiner, L. M. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res., 53: 4026-4034, 1993.
43. Hu, S., Shively, L., Raubitschek, A., Sherman, M., Williams, L. E., Wong, J. Y., Shively, J. E., and Wu, A. M. Minibody. A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res., 56: 3055-3061, 1996.
44. Pastan, I., Lovelace, E. T., Gallo, M. G., Rutherford, A. V., Magnani, J. L., and Willingham, M. C. Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas. Cancer Res., 51: 3781-3787, 1991.
45. Brinkmann, U., and Pastan, I. Immunotoxins against cancer. Biochim. Biophys. Acta, 1198: 27-45, 1994.
46. Kortt, A. A., Lah, M., Oddie, G. W., Gruen, C. L., Burns, J. E., Pearce, L. A., Atwell, J. L., McCoy, A. J., Howlett, G. J., Metzger, D. W., Webster, R. G., and Hudson, P. J. Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five- and ten-residue linkers form dimers and with zero-residue linker a trimer. Prot. Eng., 10: 423-433, 1997.
47. Reist, C. J., Batra, S. K., Pegram, C. N., Bigner, D. D., and Zalutsky, M. R. In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: comparison with its murine parent. Nucl. Med. Biol., 24: 637-647, 1997.
48. Weiner, L. M., Houston, L. L., Huston, J. S., McCartney, J. E., Tai, M. S., Apell, G., Stafford, W. F., III, Bookman, M. A., Gallo, J. M., and Adams, G. P. Improving the tumor-selective delivery of single-chain Fv molecules. Tumor Target., 1: 51-60, 1995.
49. Nieroda, C. A., Milenic, D. E., Carrasquillo, J. A., Scholm, J., and Greiner, J. W. Improved tumor radioimmunodetection using a single-chain Fv and γ-interferon: potential clinical applications for radioimmunoguided surgery and γ scanning. Cancer Res., 55: 2858-2865, 1995.
50. Wu, A. M., Chen, W., Raubitschek, A., Williams, L. E., Neumaier, M., Fischer, R., Hu, S. Z., Odom-Maryon, T., Wong, J. Y., and Shively, J. E. Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers. Immunotechnology, 2: 21-36, 1996.
51. Webber, K. O., Kreitman, R. J., and Pastan, I. Rapid and specific uptake of anti-Tac disulfide-stabilized Fv by interleukin-2 receptor-bearing tumors. Cancer Res., 55: 318-323, 1995.
52. 125I-labeled anti-Tac disulfide-stabilized Fv fragments in nude mice with interleukin 2α receptor-positive tumor xenografts. Cancer Res., 55: 5323-5329, 1995.
53. Adams, G. P., McCartney, J. E., Wolf, E. J., Eisenberg, J., Huston, J. S., Bookman, M. A., Moldofsky, P., Stafford, W. R., Houston, L. L., and Weiner, L. M. Enhanced tumor specificity of 741F8-1 (sFv′)2, an anti-c-erbB-2 single-chain Fv dimer, mediated by stable radioiodine conjugation. J. Nucl. Med., 36: 2276-2281, 1995.
54. Bobo, R. H., Laske, D. W., Akbasak, A., Morrison, P. F., Dedrick, R. L., and Oldfield, E. H. Convection-enhanced delivery of macromolecules in the brain. Proc. Natl. Acad. Sci. USA, 91: 2076-2080, 1994.
55. Lieberman, D. M., Laske, D. W., Morrison, P. F., Bankiewicz, K. S., and Oldfield, E. H. Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J. Neurosurg., 82: 1021-1029, 1995.
56. Ning, S., Trisler, K., Brown, D. M., Yu, N. Y., Kanekal, S., Lundsten, M. J., and Knox, S. J. Intratumoral radioimmunotherapy of a human colon cancer xenograft using a sustained-release gel. Radiother. Oncol., 39: 179-189, 1996.
57. Rowlinson-Busza, G., Bamias, A., Krausz, T., and Epenetos, A. A., Uptake and distribution of specific and control monoclonal antibodies in subcutaneous xenografts following intratumor injection. Cancer Res., 51: 3251-3256, 1991.